Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly Cash from Investing Activities came in at -$129000.0 in Q1 2026, down 38.71% year-on-year from -$210473.7 in Q1 2025, and up 85.75% quarter-over-quarter from -$905000.0 in Q4 2025.
Northwest Biotherapeutics (NWBO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$129000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 38.71% year-over-year to -$129000.0 in Q1 2026; TTM through Mar 2026 was -$1.9 million, a 113.25% decrease from a year earlier, with the FY2025 full-year figure at -$1.8 million, down 78.99% from the prior year.
- Cash from Investing Activities climbed to -$129000.0 in Q1 2026 per NWBO's latest filing, from -$905000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$58000.0 in Q1 2022 and bottomed at -$2.2 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$408000.0 (2022), against an average of -$546882.4.
- Across the five-year window, Cash from Investing Activities surged 89.74% in 2022 and sank 2198.28% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$2.2 million in 2022, then jumped by 80.65% to -$418000.0 in 2023, then soared by 81.34% to -$78000.0 in 2024, then sank by 1060.26% to -$905000.0 in 2025, then soared by 85.75% to -$129000.0 in 2026.
- Per Business Quant, the three latest NWBO Cash from Investing Activities figures stand at -$129000.0 (Q1 2026), -$905000.0 (Q4 2025), and -$513000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Northwest Biotherapeutics | 272.75 Mn | 270.97 Mn | - | -129,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129,000.00 |
| Mar 31, 2026 | -129,000.00 |
| Dec 31, 2025 | -905,000.00 |
| Dec 31, 2025 | -905,000.00 |
| Sep 30, 2025 | -513,000.00 |
| Sep 30, 2025 | -513,000.00 |
| Jun 30, 2025 | -304,000.00 |
| Jun 30, 2025 | -304,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Mar 31, 2025 | -93,000.00 |
| Dec 31, 2024 | -78,000.00 |
| Dec 31, 2024 | -78,000.00 |
| Sep 30, 2024 | -176,000.00 |
| Sep 30, 2024 | -176,000.00 |
| Jun 30, 2024 | -521,000.00 |
| Jun 30, 2024 | -521,000.00 |
| Mar 31, 2024 | -239,000.00 |
| Mar 31, 2024 | -239,000.00 |
| Dec 31, 2023 | -418,000.00 |
| Dec 31, 2023 | -418,000.00 |